Novartis said that it is exploring an additional direct-to-employer model to increase access and affordability for ...

Cosentyx, an autoimmune disease therapy that cost the healthcare industry $7.7 billion in 2024, will be offered at a 55% discount beginning in ...

Credit: Novartis The IV formulation is supplied as a 125mg/5mL solution in a single-dose vial and requires dilution prior to administration. The Food and Drug Administration (FDA) has approved an ...

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections to treat several inflammatory conditions. Adults and certain children can receive this medication to treat ...

The FDA has approved an intravenous formulation of Cosentyx for use in patients with psoriatic arthritis, ankylosing spondylitis and nonradiographic axial spondyloarthritis, according to a press ...

Novartis’ immunology drug Cosentyx (secukinumab) notched its sixth indication, gaining U.S. approval as a hidradenitis suppurativa (HS) therapy, the drugmaker said this week. The regulatory OK makes ...

Novartis has come up short in its bid to expand its blockbuster drug Cosentyx to an autoimmune disease whose only biologic treatment options are an old Roche drug and the biosimilars that have ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA’s approval of Cosentyx was the most read Healio ...

Novartis (NYSE:NVS) is throwing in the towel on a phase 3 program to gain an additional approval for its blockbuster Cosentyx (secukinumab) for active peripheral spondyloarthritis. The change in plans ...